Syneron Medical to Participate in Leerink Partners 6th Annual Global Healthcare Conference

IRVINE, Calif., Feb. 13, 2017 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that Hugo Goldman, Chief Financial Officer, and Phillipe Schaison, Chief Executive Officer of Syneron Candela North America and Global Executive Vice President Strategy and Business Development, are scheduled to participate in Leerink Partners 6^th Annual Global Healthcare Conference on February 16, 2017 in New York City. The conference will allow institutional investors to meet with Mr. Goldman and Dr. Schaison and will include a fireside chat presentation.

The fireside chat presentation will be webcast live over the Internet and can be accessed through the Investor Relations section on Syneron's website at www.investors.syneron.com  Please go to the website a few minutes early, as it may be necessary to download audio software to hear the presentation. In addition, a replay of the presentation will be available for 90 days.

About Syneron Candela:
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.  The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, women's intimate wellness treatments, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, CO2RE, CO2RE Intima, Profound and elōs Plus.

Founded in 2000, the company markets, services and supports its products in 86 countries.  It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

SOURCE Syneron Medical Ltd.